Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-20 6:57 pm Sale |
2023-02-16 | 13D | Galera Therapeutics, Inc. GRTX |
Sofinnova Venture Partners IX L.P. | 0 0.000% |
-3,083,712 (Position Closed) |
Filing History |
| 2023-02-03 7:04 pm Sale |
2022-11-09 | 13D | Galera Therapeutics, Inc. GRTX |
Sofinnova Venture Partners IX L.P. | 3,083,712 10.800% |
-1,098 (-0.04%) |
Filing History |
| 2021-03-04 06:17 am Sale |
2020-08-06 | 13D | Entasis Therapeutics Holdings Inc. ETTX |
Sofinnova Venture Partners IX L.P. | 0 0.000% |
-1,180,178 (Position Closed) |
Filing History |
| 2020-08-19 11:58 am Purchase |
2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI |
Sofinnova Venture Partners IX L.P. | 3,606,707 16.800% |
3,606,707 (New Position) |
Filing History |
| 2020-06-05 4:48 pm Sale |
2020-06-02 | 13D | Iterum Therapeutics plc ITRM |
Sofinnova Venture Partners IX L.P. | 410 0.000% |
-115,101 (-99.64%) |
Filing History |
| 2020-04-27 1:04 pm Sale |
2020-04-17 | 13D | Merus N.V. MRUS |
Sofinnova Venture Partners IX L.P. | 1,311,039 4.500% |
-439,060 (-25.09%) |
Filing History |